274 related articles for article (PubMed ID: 22624736)
1. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
[TBL] [Abstract][Full Text] [Related]
2. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
5. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
6. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.
Alvarez E; Ciudad A; Olivares JM; Bousoño M; Gómez JC
J Clin Psychopharmacol; 2006 Jun; 26(3):238-49. PubMed ID: 16702888
[TBL] [Abstract][Full Text] [Related]
7. Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Peuskens J; Gillain B; De Graeve D; Van Vleymen B; Albert A
Eur Psychiatry; 2009 Apr; 24(3):154-63. PubMed ID: 19118983
[TBL] [Abstract][Full Text] [Related]
8. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
9. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG
Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749
[TBL] [Abstract][Full Text] [Related]
10. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
11. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.
Hong J; Novick D; Brugnoli R; Karagianis J; Dossenbach M; Haro JM
BMC Psychiatry; 2012 Dec; 12():218. PubMed ID: 23206324
[TBL] [Abstract][Full Text] [Related]
12. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
13. One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study.
Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
Pragmat Obs Res; 2012; 3():41-49. PubMed ID: 27774016
[TBL] [Abstract][Full Text] [Related]
14. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
[TBL] [Abstract][Full Text] [Related]
16. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.
Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
Curr Med Res Opin; 2008 May; 24(5):1399-405. PubMed ID: 18397549
[TBL] [Abstract][Full Text] [Related]
17. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
18. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
Robinson DG; Woerner MG; Napolitano B; Patel RC; Sevy SM; Gunduz-Bruce H; Soto-Perello JM; Mendelowitz A; Khadivi A; Miller R; McCormack J; Lorell BS; Lesser ML; Schooler NR; Kane JM
Am J Psychiatry; 2006 Dec; 163(12):2096-102. PubMed ID: 17151160
[TBL] [Abstract][Full Text] [Related]
20. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]